Fungal co-infections are increasingly reported in hospitalized COVID-19 patients; but their clinical significance remains uncertain. We conducted a retrospective cohort study of 3373 hospitalized patients with COVID-19 to evaluate the association between fungal isolates and in-hospital mortality. Fungal isolates were identified in 197 (5.8%) patients, predominantly from respiratory specimens, with non-albicans Candida species accounting for most isolates. Patients with fungal isolates were older, had longer hospital stays, and exhibited higher rates of comorbidities, intensive care use, and exposure to broad-spectrum antibiotics, corticosteroids, and tocilizumab. In-hospital mortality was higher among patients with fungal isolates (18.8% vs. 12.2%, p=0.009). However, in multivariable logistic regression analysis, fungal isolates were not independently associated with mortality (adjusted OR 1.49, 95% CI 0.97-2.29). Mortality was independently associated with age, chronic kidney disease, immunosuppression, and treatment-related factors. These findings suggest that fungal isolates are more likely markers of disease severity and treatment exposure rather than direct contributors to mortality.